Skip to main content

Achilles Therapeutics plc (ACHL)

NASDAQ: ACHL · Delayed Price · USD
5.82
-0.01 (-0.17%)
Pre-market:Sep 20, 2021 7:36 AM EDT
5.83
-0.01 (-0.17%)
At close: Sep 17, 4:00 PM
Market Cap236.72M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out40.60M
EPS (ttm)-5.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,391
Open5.81
Previous Close5.84
Day's Range5.52 - 5.90
52-Week Range5.45 - 18.95
Betan/a
Analystsn/a
Price Target19.83 (+240.1%)
Est. Earnings DateNov 10, 2021

About ACHL

Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens. We refer to this novel class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the uniqu...

IndustryBiotechnology
IPO DateMar 31, 2021
CEOIraj Ali, Ph.D.
Employees153
Stock ExchangeNASDAQ
Ticker SymbolACHL
Full Company Profile

Financial Performance

Financial Statements

News

Achilles Therapeutics to Present at Upcoming Investor Conferences

LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

2 weeks ago - GlobeNewsWire

Achilles Therapeutics Announces Grant of US and European Patents

LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...

3 weeks ago - GlobeNewsWire

Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

– Presentations of translational science data at AACR and ASCO illustrate crucial path to potency assay –

1 month ago - GlobeNewsWire

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator -

2 months ago - GlobeNewsWire

Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -

4 months ago - GlobeNewsWire

Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...

4 months ago - GlobeNewsWire

Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Adviso...

LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors,...

4 months ago - GlobeNewsWire

Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study a...

LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today present...

5 months ago - GlobeNewsWire

Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

5 months ago - GlobeNewsWire

UK-based Achilles Therapeutics unveils US$175.5mln IPO at Nasdaq debut

Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therap...

5 months ago - Proactive Investors

Achilles Therapeutics Announces Pricing of Initial Public Offering

LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...

5 months ago - GlobeNewsWire

UK-based biotech Achilles Therapeutics files for a $100 million US IPO

Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, filed on Monday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

Achilles Therapeutics IPO Registration Document (S-1)

Achilles Therapeutics plc has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC